A phase 3b, double-blind, multicenter, randomized study to compare the efficacy and safety of single dose dalbavancin to a two dose regimen of dalbavancin for the treatment of acute bacterial skin and skin structure infections

Trial Profile

A phase 3b, double-blind, multicenter, randomized study to compare the efficacy and safety of single dose dalbavancin to a two dose regimen of dalbavancin for the treatment of acute bacterial skin and skin structure infections

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Oct 2017

At a glance

  • Drugs Dalbavancin (Primary)
  • Indications Bacterial infections; Skin and soft tissue infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Durata Therapeutics
  • Most Recent Events

    • 08 Oct 2017 Results of a subgroup analysis assessing the efficacy and safety of dalbavancin as treatment for ABSSSI in patients with Systemic Inflammatory Response Syndrome, presented at the IDWeek 2017.
    • 08 Oct 2017 Results of post hoc subgroup analysis assessing efficacy of dalbavancin for ABSSSI in patients with and without diabetes presented at the IDWeek 2017
    • 08 Oct 2017 Results of subanalysis assessing efficacy and safety of dalbavancin for the treatment of ABSSSI among overweight and obese patients presented at the IDWeek 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top